Skip to main content
Nature Communications logoLink to Nature Communications
. 2020 Apr 1;11:1716. doi: 10.1038/s41467-020-15532-1

Author Correction: A next-generation tumor-targeting IL-2 preferentially promotes tumor-infiltrating CD8+ T-cell response and effective tumor control

Zhichen Sun 1,2, Zhenhua Ren 3, Kaiting Yang 1,2, Zhida Liu 3, Shuaishuai Cao 1,2, Sisi Deng 2, Lily Xu 4, Yong Liang 1, Jingya Guo 1,2, Yingjie Bian 1, Hairong Xu 1, Jiyun Shi 5, Fan Wang 5,6, Yang-Xin Fu 3,, Hua Peng 1,
PMCID: PMC7113269  PMID: 32238807

Correction to: Nature Communications 10.1038/s41467-019-11782-w, published online 28 August 2019.

The original version of this Article contained an error in the Results section, which incorrectly read ‘Erb-sumIL2 did not make any change for tumor control when used after afatinib treatment. However, the administration of afatinib and the Erb-sumIL2 at the same time effectively control tumor growth and prevent tumor development after being rechallenged with a high dose of tumor cells (Fig. 5f).’ The correct version replaces ‘Erb-sumIL2’ with ‘Her-sumIL2’ in two instances. This has been corrected in both the PDF and HTML versions of the Article.

Contributor Information

Yang-Xin Fu, Email: yang-xin.fu@utsouthwestern.edu.

Hua Peng, Email: hpeng@moon.ibp.ac.cn.


Articles from Nature Communications are provided here courtesy of Nature Publishing Group

RESOURCES